- Home
- FLX vs ARCT Comparison
FLX vs ARCT Comparison
Compare FLX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- ARCT
- Stock Information
- Founded
- FLX 2013
- ARCT 2013
- Country
- FLX China
- ARCT United States
- Employees
- FLX N/A
- ARCT N/A
- Industry
- FLX
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- ARCT Health Care
- Exchange
- FLX NYSE
- ARCT Nasdaq
- Market Cap
- FLX 603.7M
- ARCT 487.0M
- IPO Year
- FLX 2024
- ARCT N/A
- Fundamental
- Price
- FLX $8.18
- ARCT $15.88
- Analyst Decision
- FLX
- ARCT Strong Buy
- Analyst Count
- FLX 0
- ARCT 8
- Target Price
- FLX N/A
- ARCT $61.00
- AVG Volume (30 Days)
- FLX 18.3K
- ARCT 405.9K
- Earning Date
- FLX 02-27-2025
- ARCT 03-06-2025
- Dividend Yield
- FLX N/A
- ARCT N/A
- EPS Growth
- FLX N/A
- ARCT N/A
- EPS
- FLX 0.19
- ARCT N/A
- Revenue
- FLX $663,142,775.00
- ARCT $160,399,000.00
- Revenue This Year
- FLX N/A
- ARCT $7.33
- Revenue Next Year
- FLX N/A
- ARCT $4.71
- P/E Ratio
- FLX $45.81
- ARCT N/A
- Revenue Growth
- FLX 1.31
- ARCT N/A
- 52 Week Low
- FLX $6.50
- ARCT $14.30
- 52 Week High
- FLX $21.95
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- ARCT 41.74
- Support Level
- FLX N/A
- ARCT $16.03
- Resistance Level
- FLX N/A
- ARCT $17.95
- Average True Range (ATR)
- FLX 0.00
- ARCT 1.29
- MACD
- FLX 0.00
- ARCT -0.07
- Stochastic Oscillator
- FLX 0.00
- ARCT 10.29
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.